Advanced search
Publication Cover
Cancer Investigation Volume 14, 1996 - Issue 3
Submit an article Journal homepage
14
Views
10
CrossRef citations to date
0
Altmetric
Original Article

High-Dose Ifosfamide by Infusion with Mesna in Advanced Refractory Sarcomas

Ibrahim Güllü Hacettepe University Institute of Oncology Ankara, Turkey
,
Şuayib Yalçin Hacettepe University Institute of Oncology Ankara, Turkey
,
GÜLten Tekuzman Hacettepe University Institute of Oncology Ankara, Turkey
,
Ibrahim Barişlta Hacettepe University Institute of Oncology Ankara, Turkey
,
Necati Alkiş Hacettepe University Institute of Oncology Ankara, Turkey
,
Ismail Çelik Hacettepe University Institute of Oncology Ankara, Turkey
,
Nurullah Zengin Hacettepe University Institute of Oncology Ankara, Turkey
,
NilÜFer Güler Hacettepe University Institute of Oncology Ankara, Turkey
,
AyŞE Kars Hacettepe University Institute of Oncology Ankara, Turkey
,
EŞMen Baltali Hacettepe University Institute of Oncology Ankara, Turkey
,
Emin Kansu Hacettepe University Institute of Oncology Ankara, Turkey
&
DinÇEr Firat Hacettepe University Institute of Oncology Ankara, Turkey
 show all
Pages 239-242 | Published online: 11 Jun 2009

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Şuayib Yalçin, Ibrahim Güllü, Ibrahim Banşta, Gülten Tekuzman, Yavuz Özişik, Ismail çelik & Ayşe Kars. (1998) Treatment of Advanced Refractory Sarcomas with Ifosfamide and Etoposide Combination Chemotherapy. Cancer Investigation 16:5, pages 297-302.
Read now
Ismail Çelik, Neslihan Başçil, Şuayib Yalçin, Ibrahim H. Güllü, Ayşe Kars, Ibrahim Barişta & Gülten Tekuzman. (1997) Ifosfamide-based Chemotherapy for Recurrent or Metastatic Hemangiopericytoma. Acta Oncologica 36:3, pages 348-348.
Read now

Articles from other publishers (8)

Mukul Arvind Gharote. (2020) Is continuous infusion of high-dose ifosfamide, a safe option? Drug review. International Journal of Molecular and Immuno Oncology 5, pages 62-66.
Crossref
Christine S. Higham, Seth M. Steinberg, Eva Dombi, Arie Perry, Lee J. Helman, Scott M. Schuetze, Joseph A. Ludwig, Arthur Staddon, Mohammed M. Milhem, Daniel Rushing, Robin L. Jones, Michael Livingston, Stewart Goldman, Christopher Moertel, Lars Wagner, David Janhofer, Christina M. Annunziata, Denise Reinke, Lauren Long, David Viskochil, Larry Baker & Brigitte C. Widemann. (2017) SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma 2017, pages 1-8.
Crossref
Jakob K. Anninga, Hans Gelderblom, Marta Fiocco, Judith R. Kroep, Antoni H.M. Taminiau, Pancras C.W. Hogendoorn & R. Maarten Egeler. (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. European Journal of Cancer 47:16, pages 2431-2445.
Crossref
Peter Ebeling, Lewin Eisele, Philipp Schuett, Sebastian Bauer, Jochen Schuette, Thomas Moritz, Siegfried Seeber & Michael Flasshove. (2008) Docetaxel and Gemcitabine in the Treatment of Soft Tissue Sarcoma – A Single-Center Experience. Onkologie 31:1-2, pages 11-16.
Crossref
Metin Tascilar, Walter J. Loos, Caroline Seynaeve, Jaap Verweij & Stefan Sleijfer. (2007) The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas. The Oncologist 12:11, pages 1351-1360.
Crossref
Wolfgang Hiddemann, Heinz Huber & Claus R. BartramH. Sauer, C. Wendtner, M. Schlemmer, R. D. Issels & W. Hiddemann. 2004. Die Onkologie. Die Onkologie 1521 1552 .
?brah??m Bari?ta, G�lten Tekuzman, ?uay??b Yal�in, ?brah??m G�ll�, N??l�fer G�ler, Yavuz �zi?ik, Ay?e Kars, ?sma??l �el??k, Alev T�rker, Kadr?? Altunda?Nurullah Zeng??n, Ay?eg�l �ner, E?men Baltali & D??n�er Firat. (2000) Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. Journal of Surgical Oncology 73:1, pages 12-16.
Crossref
S. Yalçin. (1999) Treatment of soft-tissue sarcomas: High-dose ifosfamide or combination of ifosfamide and etoposide?. Annals of Oncology 10:1, pages 123.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.